IP Library Granted Patent US 8,911,788
Granted Patent B2
US 8,911,788 · App. 12/767,248 · Granted Dec 16, 2014

Galenical system for active transport, method for preparation and use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,911,788
App. No.
12/767,248
Granted
Dec 16, 2014
Kind
B2
Abstract

The invention relates to a novel galenical system for taste masking, protecting an active substance, in particular in an acid medium, modulating releasing properties, masking mucous irritability and toxicity of certain active substances, for preparing aqueous forms which have a masked taste, are stable and pH independent. Said invention also relates, in particular to a galenical system which is embodied in the form of lipidic solid particles and strictly hydrophobic and devoid of water, surface active agents, emulsifiers, solvent traces and which is characterized in that it comprises at least one type of hydrophobic wax and at least one type of fatty non-neutralized acid.

Claims (41)

1. A galenic system in the form of strictly hydrophobic solid lipidic particles comprising at least one hydrophobic wax; at least one non-neutralized fatty acid; and an active constituent that has been eliminated from the surface of the lipidic particles by washing said particles with a washing mixture comprising ethanol, wherein the particles have a size between 0.5 microns and 1,500 microns, contain no water, surfactants, emulsifying agents, or traces of solvents, and have a melting temperature between 15° C. and 75° C.

2. A galenic system according to claim 1 , wherein said galenic system is solid at a temperature of up to 45° C.

3. A galenic system according to claim 1 , wherein the lipidic particles are in a spherical form.

4. A galenic system according to claim 1 , wherein the hydrophobic wax is a vegetable, animal or mineral wax, or a mix of at least one wax and at least one non-amphiphilic oil.

5. A galenic system according to claim 1 , wherein the quantity of wax is between 0.5% and 99%.

6. A galenic system according to claim 1 , wherein the melting point of the wax is between 15° C. and 75° C.

7. A galenic system according to claim 1 , wherein the wax is chosen from among triglycerides and derivatives, palm oil, Carnauba wax, Candellila wax, Alfa wax, cocoa butter, ozokerite, vegetable waxes, beeswaxes and modified beeswaxes.

8. A galenic system according to claim 1 , wherein the non-neutralized fatty acid is chosen from among fatty acids with linear chains with between 4 and 18 carbon atoms.

9. A galenic system according to claim 1 , wherein the fatty acid has a content by mass of between 0.5% and 75%.

10. A galenic system according to claim 1 , wherein said galenic system in the form of lipidic particles with a size of between 10 microns and 250 microns.

11. A galenic system according to claim 1 , having a melting temperature between 30° C. and 45° C., after incorporation of the active constituent.

12. A galenic system according to claim 1 , wherein the capacity of the particles for holding the active constituent varies from 0.02% to 75% by weight of the particles.

13. A galenic system according to claim 1 , wherein the capacity of the particles for holding the active constituent varies from 5 to 50%.

14. A galenic system according to claim 1 , wherein said galenic system solid at a temperature of up to 37.5° C.

15. A galenic system according to claim 1 , wherein the quantity of wax is between 1% and 55%.

16. A galenic system according to claim 1 , wherein the melting point of the wax is between 30° C. and 45° C.

17. A galenic system according to claim 1 , wherein the wax is olive wax, rice wax, hydrogenated jojoba wax or absolute flower waxes.

18. A galenic system according to claim 1 , wherein the non-neutralised fatty acid is myristic acid, lauric acid, palmitic acid or oleic acid.

19. A galenic system according to claim 1 , wherein the fatty acid has a content by mass of between 1% and 30%.

20. A galenic system according to claim 1 , further comprising a mineral filler.

21. A galenic system according to claim 1 , wherein the active ingredient is selected from the group consisting of hydrophilic compounds and hydrophobic compounds.

22. A galenic system according to claim 1 , wherein the active ingredient is selected from the group consisting of antibiotics, antifungicides, antiparasites, anti-malaria agents, adsorbents, hormones and derivatives, nicotine, antihistamines, steroidal and non-steroidal anti-inflammatory agents, antiallergic agents, antalgics, local anaesthetics, antivirals, antibodies and molecules acting on the immunitary system, cytostatics and anticancer agents, antalgics, hypolipemiants, vasodilators, vasoconstrictors, inhibitors of the angiotensin and phosphodiesterase conversion enzyme, nitrated and antianginal derivatives, betablocking agents, calcium inhibitors, antidiuretics and diuretics, bronchodilators, opiates and derivatives, barbiturates, benzodiazepines, molecules acting on the central nervous system, nucleic acids, peptides, anthracenic compounds, paraffin oil, polyethylene glycol, mineral salts, antispasmodic agents, gastric antisecretion agents, clay and polyvinylpyrrolidone gastric cytoprotectors, starch, and mixtures thereof.

23. A galenic system according to claim 1 , wherein the at least one hydrophobic wax is present in an amount ranging from 1% to 50%.

24. A galenic system according to claim 1 , wherein the at least one hydrophobic wax is present in an amount of about 80%.

25. A galenic system according to claim 1 , wherein the at least one hydrophobic wax is present in an amount of about 70%.

26. A galenic system according to claim 1 , wherein the at least one hydrophobic wax is present in an amount of about 50%.

27. A galenic system according to claim 26 , wherein the at least one hydrophobic wax is beeswax.

28. A process for preparing the galenic system according to claim 1 , comprising:

a.) hot mixing the wax and the non-neutralized fatty acid, while stirring, at 2° C. or 3° C. above the melting point of the compound with the highest melting point;

b.) forming lipidic droplets comprising the active constituent by dispersing the wax/fatty acid mixture obtained in the first step in a gel, wherein said gel:

i.) is immiscible with said mixture;

ii.) has been adjusted to be the same temperature as the wax/fatty acid mixture with which it is mixed; and

iii.) contains a gelling agent at a concentration between 0.1 g/L to 30 g/L;

c.) immediately at the end of injection, cooling the droplets below the solidification temperature of the mix and washing the formed particles with a washing mixture comprising ethanol; and

d.) recovering the washed particles by sieving and drying.

29. A composition comprising at least one galenic system containing an active constituent as described in claim 1 .

30. A composition according to claim 29 , contained in a cosmetic, pharmaceutical, veterinary or food composition.

31. A composition according to claim 29 , to be used for oral administration or by injection.

32. A process according to claim 28 , wherein the gelling agent is present at a concentration between 0.2 g/L and 20 g/L.

33. A process according to claim 28 , wherein the washing mixture contains between 0% and 25% ethanol.

34. A process according to claim 28 , wherein the gel is prepared with a shear thinning and non-surface active gelifying agent chosen among carboxyvinyl polymers such as polyacrylic polymers not modified by hydrophobic groups or surfactants, carrageenans, thickeners and polysaccharidic gels such as xanthenes, guar and carob gums, alginates, cellulose derivatives, pectins, agar or a mix of these products.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jul 10, 2017
From: UBS AG, STAMFORD BRANCH
To: CAPSUGEL BELGIUM BVBA
Reel/Frame 043136/0353 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2013
From: IOUALALEN, KARIM; RAYNAL, ROSANNE
To: CAPSUGEL FRANCE SAS
Reel/Frame 031628/0146 →
SECURITY AGREEMENT Recorded Aug 29, 2011
From: CAPSUGEL BELGIUM BVBA
To: UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT
Reel/Frame 026820/0766 →
DEED OF SALE OF BUSINESS ORALANCE PHARMA TO CAPSUGEL FRANCE Recorded Jun 30, 2011
From: ORALANCE PHARMA
To: CAPSUGEL FRANCE
Reel/Frame 026527/0333 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2010
From: IOUALALEN, KARIM; RAYNAL, ROSE-ANNE
To: ORALANCE PHARMA
Reel/Frame 024451/0078 →